Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Overview
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Companies Involved in Therapeutics Development
Bayer AG
Boston Pharmaceuticals Inc
Les Laboratoires Servier SAS
Netherlands Translatiol Research Center BV
NMS Group SpA
Pfizer Inc
Voronoi
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Drug Profiles
BAY-1217389 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-271850 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFI-402257 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRC-00660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRC-15010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-81694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mps1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Tyrosine Threonine Kise for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRN-081569 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Dormant Products
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Discontinued Products
Dual Specificity Protein Kise TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kise or TTK or EC 2.7.12.1) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: Servier presents update on S-81694 at ASH 2019
Oct 07, 2019: UK study finds drug that could help treat aggressive breast cancers
Oct 05, 2019: New evolution-busting drug overcomes resistance in aggressive breast cancers
Apr 20, 2017: Experimental drug could lead to potent combition in breast and other cancers
Sep 24, 2015: Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial
Oct 29, 2012: Nerviano Medical Sciences To Present Four Posters At 24th EORTC-NCI-AACR Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Boston Pharmaceuticals Inc, H2 2019
Pipeline by Les Laboratoires Servier SAS, H2 2019
Pipeline by Netherlands Translational Research Center BV, H2 2019
Pipeline by NMS Group SpA, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Voronoi, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019